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Aortic Regurgitation with the CoreValve vs. the SAPIEN XT Valve After
Transcatheter Aortic Valve Replacement
Sarkis Kiramijyan, Marco A. Magalhaes, Edward Koifman, Ricardo O. Escarcega,
Nevin C. Baker, Rebecca Torguson, Michael J. Lipinski, Hideaki Ota, Smita I. Negi,
Romain Didier, Thibault Lhermusier, Won Yu Kang, Wenjie Tian, Petros Okubagzi,
William O. Suddath, Itsik Ben-Dor, Lowell F. Satler, Augusto D. Pichard, Ron Waksman
BACKGROUND Aortic regurgitation (AR) after transcatheter aortic valve replacement
(TAVR) has been associated with worse outcomes, and a direct comparison of the
rates of AR between a self-expanding and a balloon-expandable system is not well
established. The study retrospectively examined the rates and severity of AR post
TAVR in an experienced high-volume tertiary center.
METHODS We compared the AR at hospital discharge among patients who underwent
transfemoral TAVR with the CoreValve (CV) vs. the SAPIEN XT Valve (XT). The
baseline, procedural and post-procedural characteristics were compared. The preva-
lence of total AR was assessed by pre-discharge transthoracic echocardiogram and
was categorized in the degree of severity as none or trace, mild, mild-to-moderate,
moderate, moderate-to-severe or severe.
RESULTS Overall, a total 188 patients (54% male, mean 82 years) who had trans-
femoral TAVR with either a CV (n¼101) or an XT (n¼87) were evaluated. There were
no statistically signiﬁcant differences in the rates of any degree of aortic regurgitation
with the CV vs. the XT (Figure). In addition, there was no evidence of more than
moderate aortic regurgitation in either group. Of note, there was a signiﬁcant dif-
ference in the rates of intra-procedural, post-valve implant re-ballooning with the CV
(15%) vs. the XT (5%), p¼0.022.
CONCLUSIONS The prevalence of post-TAVR AR in an experienced high-volume
center is similar between the CV and the XT valve when performed by experienced
operators with optimal post-valve implant re-ballooning, as deemed appropriate.A
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TCharacteristic CV (n[101) XT (n[87) p-ValueRe-ballooning post valve implant 15% (14/94) 5% (4/86) p¼0.022
No or trace pre-DC AR 21% (17/83) 26% (20/78) p¼0.437
Mild pre-DC AR 68% (56/83) 64% (50/78) p¼0.653
Mild-to-moderate pre-DC AR 8% (7/83) 5% (4/78) p¼0.406
Moderate pre-DC AR 4% (3/83) 5% (4/78) p¼0.713
Moderate-to-severe pre-DC AR 0% 0% ————Severe pre-DC AR 0% 0% ————LEFT ATRIAL APPENDAGE
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Intentional Right Atrial Exit For Microcatheter Infusion Of Pericardial Carbon
Dioxide Or Iodinated Contrast To Facilitate Sub-xiphoid Access
Toby Rogers, Kanishka Ratnayaka, William Schenke, Anthony Faranesh,
Jonathan Mazal, William O’Neill, Adam Greenbaum, Robert Lederman
NHLBI, National Institutes of Health, Bethesda, MD
BACKGROUND Sub-xiphoid access to the ‘dry’ pericardium is required for structural
and electrophysiological procedures, but is associated with signiﬁcant risk of right
ventricular or coronary artery laceration. If present, an effusion protects the heart
from needle injury by separating the myocardium from the pericardium. We
demonstrate a novel technique to separate visceral and parietal pericardial layers to
facilitate ease and improve safety of sub-xiphoid access.
METHODS The right atrial appendage is catheterized (Fig 1A) and then punctured
using a guidewire, over which a small trans-atrial catheter is advanced into the
pericardium (Fig 1B-C). Contrast (e.g. CO2) is infused to separate pericardial layers
(Fig 1D-E). Sub-xiphoid access is then obtained using standard technique (Fig F-H).
RESULTS Trans-atrial pericardial access was obtained in a total of 30 Yorkshire swine
using 4Fr or 2.8Fr catheters. In 16 animals, trans-atrial catheters were withdrawn
under anticoagulation and MRI was performed to monitor for pericardial hemorrhage.
In 14 animals, iodinated contrast or CO2 was infused before sub-xiphoid access was
obtained. Small effusions (mean 18.5mL) were observed after 4Fr (1.3mm outer-
diameter) but not after 2.8Fr (0.9mm outer-diameter) trans-atrial catheter withdrawal
despite full anticoagulation (mean activated clotting time 383sec), with no hemody-
namic compromise. Pericardial CO2 resorbed spontaneously within 15min and no
coronary compression was observed (Fig I).
CONCLUSION Intentional trans-atrial exit into the pericardium using small catheters
is safe and permits infusion of CO2 or iodinated contrast to separate pericardial layers
and facilitate sub-xiphoid access. 2.8Fr trans-atrial catheter withdrawal does not
cause any pericardial hemorrhage, even under full anticoagulation.CRT-818
Preclinical Study of Novel Generation Watchman FLX Performance for Left Atrial
Appendage (LAA) Occlusion
Dongming Hou, Brian Tischler, Alex Pﬂugfelder, Mindy Jedlicki, Holly Coleman,
Jason Kilvington, Kenneth Stein, Barbara Huibregtse
BSC, Marlborough, MA
BACKGROUND Percutaneous LAA closure is an alternative therapy for prevention of
stroke in high risk patients with nonvalvular AF. Clinical data has demonstrated that
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Tthe Watchman (Boston Scientiﬁc, Marlborough, MA) is as effective as warfarin for the
reduction the risk of stroke, systemic embolism and cardiovascular mortality in this
population. A new generation of Watchman FLX (WM-FLX) has been designed to
further improve implant performance. The key design changes in the WM-FLX
include an increased number of struts, an a traumatic closed distal end, and a reduced
length. The WM-FLX can be redeployed after either full or partial recapture. In
contrast, the CG-WM has to be replaced if a full recapture is needed. The present
study is aimed to evaluate the WM-FLX device in a canine LAA model.
METHODS AND RESULTS 20 dogs were used in the study. Under TEE at 0, 45, 90 and
135 views and x-ray guidance, the device was appropriately sized at the LAA ostium.
Device deployment was attempted in all animals; of which 100% of WM-FLX (12/12)
and 75% of CG-WM (6/8) were successfully deployed. Of the two unsuccessful im-
plants, one was due to pericardial effusion and the other was due to unfavorable
anatomy. All implanted animals survived to 45 or 90d. At termination, no thrombus
was observed upon gross examination. Histopathology showed all of the devices to be
well-seated in the LAA ostium at 45 and 90d, and covered by a layer of neo-endo-
cardial tissue.
CONCLUSION The next generation Watchman FLX device has improved delivery,
with fewer devices partial or full recaptures compared to the CG-WM. Furthermore,
the WM-FLX device resulted in a better seal with no leaks compared to the CG-WM,
though neither device showed residual leaks in excess of 2 mm. The healing response
in WM-FLX was comparable to CG-WM, and no evidence of a safety risk was identiﬁed
in either cohort at either time point.
Overall Implantation ParametersCG-WM WM-FLXDogs 6 12Total devices used 10 12Full recaptures required 4 2Partial recaptures 3 3Peri-device jet (<2mm) 2 0MITRAL VALVE
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Immediate In-hospital Complications of Percutaneous Transvenous Mitral
Commissurotomy in patients with Mitral Stenosis
Dr. Md.Touﬁqur Rahman, Afzalur Rahman, Abdullah Al Shaﬁ Majumder,
Syed Azizul Haque
National Institute of Cardiovascular Diseases, Dhaka, Dhaka, Bangladesh
BACKGROUND Rheumatic mitral stenosis is a very common problem in our popula-
tion having an incidence of 54 percent among rheumatic heart disease with a female
preponderance of 2:1. Percutaneous balloon mitral commissurotomy is appealing
because the mechanism of valve dilation closely parallels the mechanism of surgical
mitral commissurotomy. The technique of balloon mitral commissurotomy has
evolved rapidly, with improvements in balloons, guide wires, and the application of
double-balloon techniques. So, we aimed to assess the immediate in-hospital com-
plications of percutaneous transvenous mitral commissurotomy (PTMC) in patients
with symptomatic moderate to severe rheumatic mitral stenosis in our population.
METHODS : A prospective study was done in National Institute of Cardiovascular
Diseases, Dhaka, Bangladesh and Al- Helal Heart Institute, Mirpur, Dhaka during the
period of August 2003 to June 2014. Nine hundred and ninety (990) patients with
rheumatic mitral stenosis who underwent PTMC were evaluated clinically, by echo-
cardiography and by catheter during and after procedure.
RESULTS After PTMC mean mitral valve area increased from 0.83  0.11 cm2 to 1.76 
0.27 cm2 as measured by echocardiography. Mitral valve gradient reduced to 11.63 
4.15 mm Hg from 28.46  03.94 mm Hg after PTMC. Mean left atrial pressure as
recorded by catheter before PTMC was 30.99  08.37 mm Hg while after PTMC it was
13.81  06.28 mm Hg. There was no procedural death. There were 4 patients in-
hospital death. 2 patients died from massive CVD after PTMC. 1 patient died from
renal failure and electrolyte imbalance, 1 patient died from multisystem organ failure
due to sepsis unrelated to PTMC. There were 2þ mitral regurgitation in 3 patients or
3þ post PTMC mitral regurgitation in 1 patient as assessed by left ventriculography.
There was no A-V block during or after PTMC.
Pericardial tamponade occurred in 5 patients post procedure and those patients
were successfully treated with pericardiocentesis in the catheterization laboratory
under echo guidance and PTMC was completed successfully. Thromboembolic events
occurred in 04 patients and in 2 patients massive CVD and in 2 patients TIA. Left to
right shunt (ASD) occurred in 30 patients.
Local vascular complications like pain, hemorrhage, hematoma occurred in 69
patients.
CONCLUSION PTMC is a very effective and safe procedure at relieving the hemody-
namic effects of rheumatic mitral stenosis. Complications during the procedure was
very few.CRT-820
25 Years Follow-up Of Percutaneous Mitral Balloon Valvotomy:
Echocardiographic Score inﬂuence, Risk Factors For Death And Major Events
Ivana Picone Borges,1 Edison Carvalho Sandoval Peixoto,2
Rodrigo Trajano Sandoval Peixoto,3 Ricardo Trajano Sandoval Peixoto,4
Vanessa Freitas Marcolla,5 Alexandre Augustus Brito Aragao6
1Governo do Estado do Rio de Janeiro - Governo do Estado do Rio de Janeiro -
Subsecretaria Militar Casa Civil, Rio de Janeiro, Brazil; 2Federal Fluminense University,
Nieroi, Brazil; 3Governo do Estado do Rio de Janeiro - Policia Militar, Rio de Janeiro,
Brazil; 4Aloysio de Castro State Institute of Cardiology, Rio de Janeiro, Brazil; 5Governo
do Estado do Rio de Janeiro - Subsecretaria Militar Casa Civil, Rio de Janeiro, Brazil;
6Military Police from Rio de Janeiro State Government, Rio de Janeiro, Brazil
Percutaneous mitral balloon valvotomy (PMBV) has emerged as an alternative to
surgical treatment of mitral stenosis.
OBJECTIVES To identify the independents predictors of death and combined events
(death, new mitral balloon valvotomy, or mitral valve surgery) in long-term follow-up
of patients undergoing PMBV.
METHODS From 1987 to 2013 a total of 312 patients were followed-up 54.031.0 (1 to
126) months. The techniques were the single-balloon (84.4%), Inoue-balloon (13.8%),
and double-balloon techniques (1.7%). The total group was divided in two: echocar-
diographic score >8 and  8 points groups. Multivariate Cox regression analysis were
performed to identify independent risk factors of long-term survival and event free
survival.
RESULTS The mean age were 38.012.6 years old (range, 13 to 83). Before the pro-
cedure, 84,42% patients had echo score  8, and 15.57% score> 8. Females comprised
85%, and 84% patients were in sinus rhythm. During follow-up, survival of the total
group was 95.5%, echo score group  8 was 98.0% and echo score > 8 was 82.2%
(p<0.0001), whereas combined event-free survival was 83.4%, 86.1%, and 68.9%,
respectively (p 8 and the presence of severe mitral valve regurgitation during the
procedure. The predictors of combined events were a previous history of mitral
valvular commissurotomy, atrial ﬁbrillation, the presence of severe mitral valve
regurgitation during the procedure and post procedure mitral valve area < 1.5 m2.
CONCLUSION PMBV is an effective procedure. Survival was high, even higher in the
group with lower echocardiographic scores. Over 2/3 of the patients were event-free
at the end of follow-up. Independents predictors of survival were pre procedure echo
score  8 and the absence of severe mitral valve regurgitation during the procedure.
CRT-821
Fully Percutaneous Transthoracic Left Atrial Access To Deliver Large
Interventional Devices
Toby Rogers, Kanishka Ratnayaka, William Schenke, Merdim Sonmez, Ozgur Kocaturk,
Jonathan Mazal, Marcus Chen, Anthony Faranesh, Robert Lederman
NHLBI, National Institutes of Health, Bethesda, MD
BACKGROUND Investigational transcatheter replacement mitral valves are bulky
devices requiring large caliber access ports. An access route (Fig 1A) that does not
impact left ventricular (LV) function could simplify device engineering and improve
patient outcomes. We hypothesized that by deﬂating a lung, it is possible to access
the left atrium (LA) through the posterior chest wall, and close the LA port using off-
the-shelf nitinol closure devices.
METHODS LA access was obtained in 2 large animal models under realtime MR (8
swine and 2 sheep) or X-ray ﬂuoroscopy (2 swine). A drain was inserted into the left
pleural space to insufﬂate with CO2 and displace the lung (arrow, Fig 1B). A needle
was introduced through the chest wall (Fig 1C) and into the LA posteriorly (Fig 1D). A
large (18Fr) sheath (arrow, Fig 1E-F) was advanced into the LA over a stiff wire. The
sheath was withdrawn and the LA puncture was closed with a nitinol closure device
(arrow, Fig 1G). Animals were re-imaged 7days later.
RESULTS Pleural access, left lung deﬂation, LA access and closure, and lung re-
inﬂation was successful in all 12 animals. There were no peri-procedural complica-
tions or mortality. After 7days, MRI conﬁrmed stable position of the LA closure device
in all (arrow, Fig 1H), only one pericardial effusion was observed and superﬁcial
wounds healed well (Fig 1I).
CONCLUSION Fully percutaneous MR guided direct LA access with large sheaths is
feasible in swine and sheep, providing access to the mitral valve without injuring the
LV myocardium. The LA port can be safely closed using off-the-shelf nitinol closure
devices. This technique could provide a simple and safe access route for transcatheter
mitral valve interventions.
